Annual Report — Form 10-K Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.21M
3: EX-10.25 Material Contract HTML 33K
4: EX-10.34 Material Contract HTML 31K
5: EX-10.46 Material Contract HTML 99K
2: EX-10.5 Material Contract HTML 42K
6: EX-23.1 Consent of Expert or Counsel HTML 21K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
16: R1 Cover HTML 87K
17: R2 Balance Sheets HTML 90K
18: R3 Balance Sheets - (Parenthetical) HTML 40K
19: R4 Statements of Operations HTML 74K
20: R5 Statements of Redeemable Convertible Preferred HTML 113K
Stock and Stockholders' Equity
21: R6 Statements of Redeemable Convertible Preferred HTML 26K
Stock and Stockholders' Equity (Parenthetical)
22: R7 Statements of Cash Flows HTML 130K
23: R8 Organization HTML 26K
24: R9 Summary of Significant Accounting Policies HTML 109K
25: R10 Other Financial Information HTML 53K
26: R11 Borrowings HTML 36K
27: R12 Commitment and Contingencies HTML 41K
28: R13 Fair Value Measurements HTML 36K
29: R14 Redeemable Convertible Preferred Stock HTML 25K
30: R15 Stockholders' Equity HTML 35K
31: R16 Stock Option Plan HTML 66K
32: R17 Income Taxes HTML 73K
33: R18 Related Parties HTML 24K
34: R19 401(k) Plan HTML 27K
35: R20 Covid-19 HTML 26K
36: R21 Summary of Significant Accounting Policies - HTML 89K
(Policies)
37: R22 Summary of Significant Accounting Policies - HTML 84K
(Tables)
38: R23 Other Financial Information - (Tables) HTML 57K
39: R24 Borrowings - (Tables) HTML 29K
40: R25 Commitment and Contingencies (Tables) HTML 51K
41: R26 Fair Value Measures and Disclosures (Tables) HTML 35K
42: R27 Stockholders' Equity (Tables) HTML 33K
43: R28 Stock Option Plan (Tables) HTML 70K
44: R29 Income Taxes (Tables) HTML 74K
45: R30 Organization - (Details) HTML 27K
46: R31 Summary of Significant Accounting Policies - HTML 41K
Revenue by Major Payers (Details)
47: R32 Summary of Significant Accounting Policies - HTML 96K
Narrative (Details)
48: R33 Summary of Significant Accounting Policies - HTML 36K
Disaggregation of Revenue (Details)
49: R34 Summary of Significant Accounting Policies - Cash, HTML 30K
cash equivalents and restricted cash (Details)
50: R35 Summary of Significant Accounting Policies - HTML 31K
Securities (Details)
51: R36 Other Financial Information - Prepaid expenses HTML 33K
(Details)
52: R37 Other Financial Information - Property and HTML 40K
equipment (Details)
53: R38 Other Financial Information - Narrative (Details) HTML 28K
54: R39 Other Financial Information - Accrued liabilities HTML 40K
(Details)
55: R40 Borrowings - Narrative (Details) HTML 58K
56: R41 Borrowings - Future minimum payments (Details) HTML 40K
57: R42 Commitment and Contingencies - Narrative (Details) HTML 50K
58: R43 Commitment and Contingencies - Minimum annual HTML 66K
lease payments under non-cancelable lease
arrangements (Details)
59: R44 Fair Value Measurements (Details) HTML 31K
60: R45 Redeemable Convertible Preferred Stock (Details) HTML 47K
61: R46 Stockholders' Equity - Narrative (Details) HTML 40K
62: R47 Stockholders' Equity (Details) HTML 38K
63: R48 Stock Option Plan - Narrative (Details) HTML 60K
64: R49 Stock Option Plan - Stock Option Activity HTML 76K
(Details)
65: R50 Stock Option Plan - Fair Value Assumptions HTML 46K
(Details)
66: R51 Stock Option Plan - Stock-Based Compensation HTML 31K
Expense (Details)
67: R52 Stock Option Plan - Common Stock Reserved For HTML 32K
Future Issuance (Details)
68: R53 Income Taxes - Components of Income Tax Expense HTML 44K
(Benefit) (Details)
69: R54 Income Taxes - Reconciliation of Effective Income HTML 38K
Tax Rate (Details)
70: R55 Income Taxes - Reconciliation of Deferred Tax HTML 51K
Assets and Liabilities (Details)
71: R56 Income Taxes - Change In Valuation Allowance HTML 27K
(Details)
72: R57 Income Taxes - Narrative (Details) HTML 33K
73: R58 401(k) Plan (Details) HTML 25K
74: R59 Covid-19 (Details) HTML 33K
76: XML IDEA XML File -- Filing Summary XML 132K
15: XML XBRL Instance -- exdx-20201231_htm XML 1.42M
75: EXCEL IDEA Workbook of Financial Reports XLSX 91K
11: EX-101.CAL XBRL Calculations -- exdx-20201231_cal XML 230K
12: EX-101.DEF XBRL Definitions -- exdx-20201231_def XML 566K
13: EX-101.LAB XBRL Labels -- exdx-20201231_lab XML 1.63M
14: EX-101.PRE XBRL Presentations -- exdx-20201231_pre XML 918K
10: EX-101.SCH XBRL Schema -- exdx-20201231 XSD 158K
77: JSON XBRL Instance as JSON Data -- MetaLinks 371± 546K
78: ZIP XBRL Zipped Folder -- 0001274737-21-000015-xbrl Zip 710K
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED.
AMENDMENT #3 TO CO-PROMOTION AGREEMENT
As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline
TRxU for October through December (4th Quarter) of 2020, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS/Anthem data for the zip codes covered by Exagen sale representatives.
The below table will replace Section 2.2.2 Adjusted Baseline TRxU figures for Quarter ending December 31st, 2020 on page 2 and Section 2.12 Adjusted Baseline TRxU 4Q20, Maximum Payment and Actual Payout for 4Q20 on page 4 in the Amendment # 2 of Co-Promotion Agreement Contract No. C2020012644 and further amended via notice dated October 29th, 2020 Contract No. C2020023283.
Q4
2020
Baseline
[***]
Max Payout
[***]
The parties have agreed that the following sections of the Agreement are hereby amended as follows effective as the date of this notice:
2.3.4.
The
terms of the Promotion Fee shall be adjusted for the quarters ending March 31, 2021 and June 30, 2021 as follows:
2.3.4.1
The Promotion Fee shall be based on a unit value for each quarter over Baseline TRxU, allocated as follows:
For
the Quantities
Promotion Fee per unit
[***]
[***]
[***]
[***]
[***]
[***]
2.3.4.2
Unit
quantities below Baseline TRxU in a quarter will be counted as zero for purposes of calculating Quantities for Promotion Fee per unit.
2.3.4.3
Janssen will pay Exagen a Minimum Promotion Fee of $300,000 for each of the quarters ending March 31, 2021 and June 30, 2021
2.3.4.4
In
addition, the Promotion Fee will be capped at an amount reflecting the payment due in the event that Exagen's TRxU exceeds 10% above the Baseline TRxU for the quarters ending March 31, 2021 and June 30, 2021.
For example:
[***]
2.3.5
For
the remaining quarters of the Contract Term Extension (July 1, 2021 – December 31, 2021) and any additional Third Term, the Promotion Fee payment terms shall revert to the terms set forth in the Co-Promotion Agreement, with no Minimum Promotion Fee and no Cap (Section 2.3.3).
***
Certain Confidential Information Omitted
In
accordance with Amendment #2 dated June 18th, 2020 to the Agreement, please find the Second Term Baseline TRxU for the First Half of 2021:
